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Long-Term Cardiovascular Outcomes After
Pregnancy in Women With Heart Disease
Samuel C. Siu , MD, SM, MBA; Douglas S. Lee , MD, PhD; Mohammed Rashid
Jiming Fang, PhD; Peter C. Austin , PhD; Candice K. Silversides, MD, SM

, MScPH;

BACKGROUND: Women with heart disease are at risk for pregnancy complications, but their long-term cardiovascular outcomes
after pregnancy are not known.
METHODS AND RESULTS: We examined long-term cardiovascular outcomes after pregnancy in 1014 consecutive women with
heart disease and a matched group of 2028 women without heart disease. The primary outcome was a composite of mortality, heart failure, atrial fibrillation, stroke, myocardial infarction, or arrhythmia. Secondary outcomes included cardiac procedures and new hypertension or diabetes mellitus. We compared the rates of these outcomes between women with and
without heart disease and adjusted for maternal and pregnancy characteristics. We also determined if pregnancy risk prediction tools (CARPREG [Canadian Cardiac Disease in Pregnancy] and World Health Organization) could stratify long-term risks.
At 20-year follow-up, a primary outcome occurred in 33.1% of women with heart disease, compared with 2.1% of women
without heart disease. Thirty-one percent of women with heart disease required a cardiac procedure. The primary outcome
(adjusted hazard ratio, 19.6; 95% CI, 13.8–29.0; P<0.0001) and new hypertension or diabetes mellitus (adjusted hazard ratio,
1.6; 95% CI, 1.4–2.0; P<0.0001) were more frequent in women with heart disease compared with those without. Pregnancy
risk prediction tools further stratified the late cardiovascular risks in women with heart disease, a primary outcome occurring
in up to 54% of women in the highest pregnancy risk category.
Downloaded from http://ahajournals.org by on June 21, 2022

CONCLUSIONS: Following pregnancy, women with heart disease are at high risk for adverse long-term cardiovascular outcomes. Current pregnancy risk prediction tools can identify women at highest risk for long-term cardiovascular events.
Key Words: cardiovascular ■ heart disease ■ long-term ■ pregnancy

A

n increasing number of women with heart disease are undergoing pregnancy, with maternal
cardiovascular disease estimated to affect 1%
to 4% of pregnancies.1,2 In the presence of maternal
heart disease, the hemodynamic stress of pregnancy
can lead to maternal deterioration, and many studies
have shown that pregnant women with heart disease
are at higher risk of adverse cardiac and obstetric outcomes compared with the pregnant women without
heart disease,1,3–8 While considerable progress has
been made in predicting and treating cardiac complications in women with heart disease during pregnancy,9–14 their long-term cardiovascular outcomes have

not been systematically examined. Determining late
outcomes is important in women with heart disease,
as they may be at risk for both cardiovascular deterioration after pregnancy as well as the development
of hypertension or diabetes mellitus, in view of the
relationship between pregnancy-
related complications and future adverse cardiovascular events.13,15
Therefore, the primary purpose of this study was
to examine long-
term cardiovascular outcomes in
women with heart disease after their pregnancy and
compare these to a matched group of women without heart disease. We hypothesized that pregnant
women with heart disease would have a higher rate
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CLINICAL PERSPECTIVE
What Is New?

• Women with heart disease are at higher risk of
late postpregnancy cardiovascular complications and new hypertension/diabetes mellitus
compared with women without heart disease.
• Risk prediction methods developed for assessment of pregnancy risk in women with heart disease can also be used to risk stratify long-term
cardiovascular risks.

What Are the Clinical Implications?

• Ongoing surveillance and risk factor modification in women with heart disease beyond pregnancy is important.
• Current tools for cardiovascular risk assessment during pregnancy can also be used to risk
stratify for long-
term cardiovascular risk after
pregnancy.

Nonstandard Abbreviations and Acronyms
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CARPREG Canadian Cardiac Disease in
Pregnancy study
ICES
Institute for Clinical Evaluative
Sciences
WHO
World Health Organization

of long-
term cardiovascular outcomes than pregnant women without heart disease. We also examined whether previously validated pregnancy risk
prediction tools could be useful to identify those
women at highest risk for long-term cardiovascular
complications.

METHODS
Study Design and Population
We conducted a retrospective matched-cohort study
in Ontario, Canada, where >99% of births occur in
hospitals and residents have universal access to
hospital and physician services.16,17 This study was
designed by the authors, approved by the local research ethics committees, conducted at ICES (formerly Institute for Clinical Evaluative Sciences), and
reported according to recommended guidelines
(Table S1). ICES is an independent, not-for-profit research institute whose legal status under Ontario’s
health information privacy law allows it to collect
and analyze healthcare and demographic data,
without consent, for health system evaluation and

improvement. The lead author (Dr Siu) had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of
the data analysis. The data set from this study is held
securely in coded form at ICES. While data-sharing
agreements prohibit ICES from making the data set
publicly available, access can be granted to those
who meet prespecified criteria for confidential access, available at www.ices.on.ca. The full data set
creation plan and underlying analytic code are available from the authors upon request, understanding
that the programs may rely upon coding templates
or macros that are unique to ICES and are therefore
either inaccessible or may require modification.
We identified and matched pregnant women with
heart disease (exposure factor) who had received care
at the Mount Sinai and Toronto General Hospital’s
pregnancy and heart disease program, with pregnant
women without heart disease identified from administrative healthcare databases at ICES. We retrieved
data from the following databases: (1) demographic
characteristics and vital statistics from Ontario’s
Registered Persons Database and (2) birth outcomes
from the MOMBABY database. The MOMBABY database links the hospital record of a delivering woman
with that of her newborn in pregnancies that progress beyond 20 weeks’ gestation or with a newborn
birth weight >500 g as recorded on the Discharge
Abstract Database at the Canadian Institute for Health
Information. Other baseline data were determined
using other ICES databases (summaries of the databases provided in Table S2). These databases have
been used extensively for healthcare research including late outcome studies of pregnant women.15,17–30
Neighborhood-
level income quintile and rural/urban
residence were determined using Statistics Canada
definitions.
We included consecutive pregnant women with
preexisting heart disease (congenital, acquired, or
cardiac arrhythmia) receiving care in the pregnancy
and heart disease program who had at least 1
birth between 1994 (establishment of the program)
and 2015 (to ensure minimum follow-up duration of
5 years). This program provides primary and tertiary
care for pregnant women with heart disease in the
Greater Toronto Metropolitan area. Patients were followed until the sixth postpartum month, after which
their ongoing care and follow-up was continued by
their primary physician or specialist. Details pertaining to the underlying cardiac lesion were recorded
for all women at their antenatal visit.3,4 The first pregnancy that progressed beyond 20 weeks’ gestation
and the corresponding birth, between 1994 and
2015, were defined as the index pregnancy and index
birth, respectively. The date of the index birth was
the cohort entry date. We matched the study cohort
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with pregnant women, also from 1994 to 2015,
without heart disease or prior cardiovascular procedures, from the general Ontario population using
the MOMBABY database. In women without heart
disease who had multiple births during that period,
a birth was randomly selected and was designated
the index birth, to enable matching with women in
the heart disease group who had births before 1994.
We derived a prognostic risk score to match
women with heart disease to women without heart
disease.31 To do so, we used the sample of pregnant
women without heart disease to regress the hazard of all-cause mortality, heart failure, myocardial
infarction, stroke, arrhythmia, or atrial fibrillation (ie,
the study’s primary composite outcome) on baseline
variables measured at the time of the index pregnancy (comorbid conditions, fertility therapy, ethnicity, multifetal births, cesarean delivery, gestational
diabetes mellitus, and site of delivery; Table S3). To
create the community comparison group of women
without heart disease, women without heart disease
were matched to each woman with heart disease on
the following: (1) prognostic risk score ±0.2 SDs, (2)
age at index birth ±1 year, (3) same fiscal year of index
birth, (4) any births before index birth, (5) residence in
metropolitan area (Toronto), and (6) income quintile.
Using these 6 factors, we matched each pregnant
woman with heart disease to 2 pregnant women
without heart disease with the same predicted risk
of subsequently developing the composite outcome
based on demographic and baseline variables. This
strategy of 1:2 matching was to improve the precision
of the risk estimates in the matched groups without a
commensurate increase in bias.32

Covariate Conditions and Pregnancy Risk
Covariate conditions and outcome were obtained
using diagnostic or procedural codes from the
International Classification of Disease Ninth Revision
(ICD-9); International Classification of Disease, Ninth
Revision, Tenth Revision, Canada (ICD-10-CA);
Canadian Classification of Diagnostic, Therapeutic,
and Surgical Procedures; Canadian Classification of
Health Interventions; and the above-mentioned ICES
databases (Table S4). Covariate conditions and outcome were defined before data analysis, as per ICES
policy.
In the heart disease group, antepartum cardiac variables and diagnosis were used to calculate the maternal cardiovascular risk during the index pregnancy
using 3 validated risk classification methods in current use that are applicable to women with a range of
cardiac conditions: the original CARPREG (Canadian
Cardiac Disease in Pregnancy) risk score,3 the expanded CARPREG II risk score,4 and the modified
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World Health Organization (WHO) classification system.14 These risk classification methods estimate the
mother’s baseline cardiovascular risk during pregnancy and the first 6 postpartum months (Table S5).
Using each method, women in the heart disease group
were classified as either low or intermediate-to-high
risk for maternal cardiovascular complications during
their index pregnancy.

Outcomes
Women were followed until death or end of the
follow-
up period (December 31, 2019), whichever
occurred earlier. The primary outcome was a composite of all-cause mortality, heart failure, myocardial
infarction, stroke, arrhythmia (including cardiac arrest, ventricular and atrial tachyarrhythmia, and heart
block), or atrial fibrillation. The secondary outcomes
were (1) components of the composite primary outcome, (2) cardiovascular death, (3) therapeutic cardiac procedures (catheter based or surgical), and (4)
incident hypertension or diabetes mellitus. For determination of outcomes, cardiovascular events that
occurred during the antepartum period or within the
first 6 postpartum months were considered to be
pregnancy related, as changes in the maternal cardiovascular system do not fully resolve until this time
has elapsed.4,33 The validated algorithms for incident
diabetes mellitus and incident hypertension exclude
gestational diabetes mellitus or hypertensive disorders of pregnancy.25,28

Statistical Analysis
All analyses were conducted using SAS Enterprise
Guide version 7.1 (SAS Institute, Cary, NC) at ICES.
Continuous variables were summarized using the median and interquartile range. To comply with ICES’s
privacy policy, we suppressed frequency counts between 1 and 5. We compared baseline characteristics
between women in the heart disease and comparison
groups using standardized differences, with a value
≥0.10 considered a potentially important difference.
Unadjusted cumulative incidence curves of outcomes
(which accounted for the appropriate competing risk
when necessary) were generated.
We fit separate Cox regression models to compare primary and secondary outcomes between
heart disease and comparison groups. When there
were competing risks (mortality not included as an
outcome), cause-
specific regression models were
used instead of Cox regression. The covariates for
each model included heart disease status, any obstetric complication (ie, ante-or postpartum hemorrhage, placental abruption, placental infarction,
premature delivery or rupture of membranes, gestational hypertension or preeclampsia/eclampsia, poor
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fetal growth, or stillbirth) during the index pregnancy,
any cardiac complication (heart failure, arrhythmia,
stroke, or myocardial infarction) during the index
pregnancy, fetal congenital heart defect during index
pregnancy, Charlson Comorbidity Index,34 and the
baseline demographic variables used in matching
(age and fiscal year of index birth, any births before
index birth, residence in Toronto metropolitan area,
income quintile). Covariates relating to outcome of
the index pregnancy (obstetric complications, cesarean delivery, and congenital heart disease in the
infant) were included because of their relationship to
subsequent cardiovascular disease in the general
population.13,15,35–37 As the matching process may
not balance all covariates including comorbid diagnoses, we adjusted for residual confounding by using
the Charlson Index, as well as the demographic variables used in the matching process. The model also
included 2 time-varying covariates for births subsequent to index pregnancy (currently pregnant; number of births after the index birth), to adjust for the
possible influence of subsequent pregnancies on
outcomes. If the hazard ratio associated with the
variable of interest (heart disease group) did not meet
the proportional hazard assumption, we computed
time-specific instantaneous hazard ratios by inclusion of a time interaction term into the models. Level
of significance was set at 0.05 (two sided).
Adjusted cumulative incidence curves were generated from the Cox regression (when mortality
was included in the outcome) or Fine-Gray models
(when mortality was not included as an outcome);
time-varying covariates were not included in these
models, as cumulative incidence functions cannot
be estimated in the presence of time-varying covariates.38 We repeated the above procedure by using
CARPREG, CARPREG II, and WHO risk groups (low
versus intermediate-to-high risk for pregnancy maternal cardiovascular complications) in place of the
heart disease group variable.
Cumulative incidence curves were truncated at the
time of follow-up, beyond which the total number of
women at risk was ≤20% of the baseline. Ninety-five
percent CIs were calculated using 1000 bootstrap
samples. A robust variance estimator was used to account for the matched nature of the sample.

RESULTS
A total of 1036 women with heart disease were eligible
for matching after excluding pregnancy-associated
deaths (n=1–5, exact number suppressed because
of ICES’s privacy policy) and applying other exclusion criteria (Figure S1). After applying the matching
algorithm, 1014 women with heart disease were successfully matched to 2028 women in the comparison
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group. The median age at the time of the index birth
was 30 years in both groups. At the time of the index
birth, a higher proportion of the heart disease group
had a Charlson score ≥1, delivered at a tertiary care
center, had an infant born with congenital cardiac
defect, or had a cardiovascular complication during
pregnancy, when compared with the comparison
group; the 2 groups were not significantly different
with respect to other characteristics (Table 1). In the
heart disease group, the most frequent maternal cardiac lesions were congenital heart defect and left-
sided valvular disease.
The maximum follow-up duration was 25 years
in both groups, with a total of 14 416 and 29 414
person-years’ follow-up for the heart disease group
and comparison group, respectively. Median follow-up duration in the heart disease (13.7 years; interquartile range, 8.6–
19.8 years) and comparison
group (14.0 years; interquartile range, 8.8–20.2) were
similar (Table 1). Data collection was complete for
all outcomes. A primary outcome occurred in 298
women in the heart disease group (25.3 events/1000
person-years) versus 32 women in the comparison
group (1.1 events/1000 person-
years) with an adjusted hazard ratio of 19.6 for the entire follow-up
period (Table 2). The adjusted cumulative incidence
of a primary outcome in the heart disease group was
20.1% at 10 years and 33.1% at 20 years of follow-up;
the corresponding cumulative incidence was 2.1%
in the comparison group at 20 years of follow-up
(Figure 1A). There was a time dependency to this
elevated hazard for the primary outcome, with the
highest hazard ratios in the earlier years of follow-up
after delivery (Figure 1B).
The adjusted rates for all-
cause mortality,
congestive heart failure, atrial fibrillation, myocardial
infarction, or stroke were higher in the heart disease
group compared with the comparison group (Table 2).
The rate of cardiovascular death was 1.0 per 1000
person-years in women with heart disease and 0.04
per 1000 person-
years in controls (crude hazard
ratio, 20.3; adjusted hazard ratio not calculated
because of very low rate in the comparison group). At
20 years of follow-up, the heart disease group had a
higher adjusted cumulative incidence of heart failure
and atrial fibrillation compared with the comparison
group (Figure 2A and 2B). The heart disease
group also frequently required therapeutic cardiac
procedures (30.6% at 20 years) and developed new
hypertension or diabetes mellitus (27.2% at 20 years),
both of which were higher than in the comparison
group (0.5% and 18.4%, cardiac procedures and
incident hypertension/diabetes mellitus, respectively)
(Figure 2C and 2D). Unadjusted cumulative incidence
curves (Figures S2 and S3) showed similar trends as
adjusted curves.
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Table 1. Baseline and Follow-Up Characteristics in Women With Heart Disease and Matched Comparison Group
Heart Disease Group (n=1014
Women)

Community Group (n=2028
Women)

Standardized
Difference

30.0 (27.0–34.0)

30.0 (27.0–34.0)

0

415 (40.9)

830 (40.9)

0

45 (4.4)

94 (4.6)

0.01

635 (62.6)

1270 (62.6)

0

At index birth
Median (IQR) maternal age, y
Low residential income area,* n (%)
Rural residence, n (%)
Residence within metropolitan area,† n (%)
Ethnicity, n (%)
Chinese

47 (4.6)

92 (4.5)

0

South Asian

39 (3.8)

68 (3.4)

0.03

928 (91.5)

1868 (92.1)

0.02

450 (44.4)

846 (41.7)

0.05

79 (7.8)

22 (1.1)

0.33

Not Chinese or South Asian
‡

Any comorbid condition, n (%)
Charlson Index ≥1, n (%)
Fertility treatment, n (%)

38 (3.7)

66 (3.3)

0.03

299 (29.5)

598 (29.5)

0

Gestational diabetes mellitus, n (%)

59 (5.8)

155 (7.6)

0.07

Multifetal pregnancy, n (%)

28 (2.8)

49 (2.4)

0.02

Delivery at tertiary center, n (%)

912 (89.9)

1345 (66.3)

0.6

Cesarean delivery, n (%)

295 (29.1)

598 (29.5)

0.01

Preterm birth, n (%)

132 (13.0)

221 (10.9)

0.07

0 (0.0)

1–5 (0.1–0.2)

0.03–0.07

303 (29.9)

536 (26.4)

0.08

Cardiac complication during index pregnancy,‖
n (%)

65 (6.4)

0 (0.0)

0.37

Infant born with congenital cardiac lesion, n (%)

91 (9.0)

35 (1.7)

0.33

0.05

Any previous births, n (%)

Stillbirth, n (%)
Obstetric complication during index pregnancy,§
n (%)
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Primary maternal cardiac diagnosis,¶ n (%)
Congenital

399 (39.3)

Cardiomyopathy

112 (11.0)

Left-sided valve disease

312 (30.8)

Isolated arrhythmia

118 (11.6)

Ischemic heart disease

26 (2.6)

Other

47 (4.6)

After index birth
13.7 (8.6–19.8)

14.0 (8.8–20.2)

Range

Median (IQR) follow-up, y

0.9–25.2

3.8–25.7

Number of women with subsequent births, n (%)

493 (48.6)

869 (42.9)

0.12

0.00 (0.00–1.00)

0.00 (0.00–1.00)

0.13

0.00–8.00

0.00–5.00

2.9 (2.1–4.4)

2.9 (2.1–4.4)

Number of subsequent pregnancies
Median (IQR)
Range
Median (IQR) interval between index birth and
next subsequent birth, y

0

IQR indicates interquartile range.
*Residing within the 2 lowest neighborhood income quintiles.
†
Residence within Greater Toronto Metropolitan Area.
‡
Any comorbid condition (hypertension, diabetes mellitus, pulmonary disease, renal disease, cancer, collagen vascular disease, thyroid disease,
cerebrovascular disease, peripheral vascular disease, dyslipidemia, obesity, or substance abuse).
§
Admission within 9 months before and including index birth, for ante-or postpartum hemorrhage, placental abruption, placental infarction, premature
delivery or rupture of membranes, gestational hypertension or preeclampsia/eclampsia, poor fetal growth, or stillbirth.
‖
Admission within 9 months before and 6 months after index birth, for heart failure, arrhythmia, stroke, or myocardial infarction.
¶
In women with multiple cardiac lesions, the diagnosis that is the most hemodynamically significant was considered to be the primary diagnosis. Lesions that
do not fall into the first 5 mutually exclusive categories were classified as other.
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205 (20.2)

142 (14.0)

23 (2.3)

281 (27.7)

209 (20.6)

Heart failure†

Atrial fibrillation†

Arrhythmia†

Myocardial infarction or
stroke†

Therapeutic cardiac
procedures

New diabetes mellitus or
hypertension
17.5 (15.3–20.0)

24.3 (21.7–27.3)

1.6 (1.1–2.4)

10.8 (9.17–12.72)

16.5 (14.4–18.9)

8.7 (7.2–10.4)

3.0 (2.2–4.0)

25.4 (22.7–28.4)

Rate per 1000 Person-Years
(95% CI)

274 (13.5)

8 (0.4)

8 (0.4)

1–5

9 (0.4)

1–5

14 (0.7)

32 (1.6)

n (%)

10.7 (9.5–12.0)

0.3 (0.1–0.5)

0.3 (0.1–0.6)

0.07‡

0.3 (0.2–0.6)

0.2 (0.1–0.4)

0.5 (0.3–0.8)

1.1 (0.8–1.5)

Rate per 1000 Person-Years
(95% CI)

Comparison
n=2028 Women (Referent)

1.7 (1.4–2.0)

105.2 (50.1–245.4)

7.0 (2.9–16.5)

184.7‡

61.8 (31.3–128.3)

65.8 (25.4–240.1)

6.8 (3.6–12.7)

24.0 (16.6–35.0)

Unadjusted HR (95%
CI)

1.6* (1.4–2.0)

83.7 (44.2–184.9)*
Year 1: 314.0 (76.3–
1292.3)
Year 5: 179.8 (59.4–
544.6)
Year 10: 89.6 (39.7–
202.2)
Year 15: 44.6
(21.3–93.4)

5.6 (2.5–13.6)

§

44.7 (24.2–94.5)*
Year 1: 153.4 (39.4–
597.0)
Year 5: 89.2 (31.9–
249.6)
Year 10: 45.3 (21.7–
94.8)
Year 15: 23.0
(10.9– 48.5)

45.7 (20.6–129.8)*

5.4 (2.9–10.4)*

19.6 (13.8–29.0)*
See Figure 1B for time
dependent HRs

Adjusted HR (95% CI)

<0.0001

<0.0001

0.0001

<0.0001

<0.0001

<0.0001

<0.0001

P Value for
Adjusted HR

HR indicates hazard ratio.
*Hazard ratio from analyses assuming constant proportional hazard between heart disease and comparison groups, instantaneous hazard ratios at 1, 5, 10, and 15 years are provided when proportional hazard
assumption was not met.
†
Secondary outcomes are not mutually exclusive.
‡
95% confidence intervals not provided as per Institute for Clinical Evaluative Sciences’ privacy policy for low counts.
§
Time-dependent hazard ratios not calculated because of low number of events in the comparison group.

43 (4.2)

117 (11.5)

All-cause mortality†

298 (29.4)

Composite outcome

n (%)

Heart Disease
n=1014 Women

Table 2. Frequency and Rate of Adverse Outcomes in Women With Heart Disease and Matched Comparison Group
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Figure 1. Adjusted time-to-event curves for primary outcome and hazard ratios.
A, Adjusted cumulative incidence of the primary outcome (all-cause mortality, heart failure, myocardial infarction, stroke, arrhythmia,
or atrial fibrillation) with 95% CIs in the heart disease group and matched comparison group. Numbers at risk were obtained from
unadjusted cumulative incidence curves. B, Instantaneous hazard ratio (point estimates and 95% CIs) of primary outcome in heart
disease group (comparison group=referent) as a function of follow-up time.

Downloaded from http://ahajournals.org by on June 21, 2022

In a secondary analysis, in which the cumulative
incidence of primary outcomes was stratified by the
occurrence of cardiac or obstetric complications

during the index pregnancy (Figure S4), the unadjusted cumulative 20-year incidence of a primary outcome in women with heart disease who experienced

Figure 2. Adjusted time-to-event curves for selected secondary outcomes.
Adjusted cumulative incidence and 95% CIs for selected secondary outcomes (heart failure [A], atrial fibrillation [B], therapeutic
cardiac procedures [C], and new hypertension or diabetes mellitus [D]) in heart disease group and matched comparison group.
Numbers at risk were obtained from unadjusted cumulative incidence curves.
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Table 3. Adjusted Model for Primary Outcome, Cardiac Procedures, and New Hypertension/Diabetes Mellitus
Primary Composite Outcome
Parameter

New Hypertension or Diabetes
Mellitus

Cardiac Procedure

HR (95% CI)

P Value

HR (95% CI)

P Value

HR (95% CI)

P Value

19.6 (13.8–29.0)*
See Figure 1B for
time-dependent HRs

<0.001

83.7 (44.2–184.9)*
See Table 2 for time-
dependent HRs

<0.001

1.6 (1.4–2.0)

<0.001

Obstetric complication during
index pregnancy

1.25 (1.0–1.6)

0.072

0.9 (0.7–1.1)

0.36

1.5 (1.2–1.8)

<0.001

Cardiac complication during
index pregnancy

3.3 (2.3– 4.6)

<0.001†

1.9 (1.3–2.8)

<0.001

1.0 (0.6–1.6)

0.98

Infant born with congenital
cardiac lesion

1.3 (0.9–1.9)

0.12

1.3 (0.9–1.9)

0.15

1.5 (1.1–2.1)

0.023

Number of subsequent
pregnancies

1.1 (0.9–1.3)

0.50

0.8 (0.6–1.0)

0.090

0.9 (0.8–1.1)

0.38

Any subsequently pregnancies

2.0 (1.3–3.0)

0.0030†

0.39 (0.16–0.79)

0.020

0.4 (0.2–0.8)

0.019

Heart disease group (community
comparison group=referent)

Charlson Index score ≥1
Age at index birth

1.5 (0.9–2.3)

0.068

1.1 (0.7–1.8)

0.68

1.4 (0.8–2.3)

0.21

1.04 (1.02–1.06)

0.0016

0.99 (0.97–1.01)

0.29

1.05 (1.04–1.07)

<0.0001

Low residential income area

1.0 (0.8–1.3)

0.77

0.9 (0.7–1.1)

0.42

1.4 (1.2–1.7)

0.0001

Greater Toronto metropolitan area
residence

1.0 (0.8–1.3)

0.87

1.2 (0.9–1.5)

0.28

1.2 (1.0–1.4)

0.14

Index birth is first pregnancy
Fiscal year of index birth

0.8 (0.7–1.1)

0.16

0.9 (0.7–1.2)

0.41

0.8 (0.6–0.9)

0.014

0.98 (0.96–0.99)

0.039†

0.97 (0.94–0.99)

0.0033

0.97 (0.95–0.99)

0.0010

HR indicates hazard ratio.
*hazard ratio from analyses assuming constant proportional hazard between heart disease and comparison groups.
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a pregnancy complication was 48.5% compared with
32.5% in women with heart disease who did not experienced a pregnancy complication. In comparison,
the cumulative incidence in women from the comparison group was 3.6% and 2.1%, with and without pregnancy complications, respectively. When
atrial fibrillation and arrhythmia were excluded from
analysis, the adjusted cumulative incidence of all-
cause mortality, heart failure, stroke, or myocardial
infarction at 20 years was 15.0% and 1.4% in the
heart disease and comparison groups, respectively
(Figure S5). The unadjusted rate of the primary outcome and the frequency of the component events,
stratified by principal cardiac diagnosis, are provided
in Table S6.
Maternal heart disease was associated with an
elevated hazard for the primary composite outcome
or cardiac procedure even after adjustment for the
statistically significant covariates such as cardiac
complications during pregnancy and maternal age
(Table 3). Similarly, the elevated hazard for incident
hypertension and diabetes mellitus associated with
maternal heart disease was after adjustment for
statistically significant covariates including obstetric complications during pregnancy, baby born with
congenital heart disease, maternal age, low residential income area, and nulliparity. The inverse relationship between fiscal year of birth and outcomes can
be attributed to the shorter follow-up time for women
with more recent births.

After the index birth, there were additional births in
48.6% of the heart disease group and 42.9% of the
comparison group, with a median time of 2.9 years between the index and subsequent birth in both groups
(Table 1). There was no significant relationship between number of subsequent births and the primary
outcome (Table 3). The hazard of having a primary
outcome was increased during the time of subsequent
pregnancy (Table 3). However, only 11.4% of the primary outcomes in the heart disease group occurred
during subsequent pregnancies (none in the comparison group); these events were either heart failure, atrial
fibrillation, or arrhythmia. Similarly, 2.4% of cardiac
therapeutic procedures performed in the heart disease
group (none in the comparison group) were in relation
to subsequent pregnancies.
Table 4 provides a summary of pregnancy risk
groups stratified by maternal cardiac lesions. The proportion of the heart disease group at intermediate-to-
high risk for cardiovascular complications during their
index pregnancy was 42%, 29%, and 30%, corresponding to CARPREG risk score >1, CARPREG II risk
score ≥4, and WHO class III or IV (estimated cardiovascular pregnancy risk of ≥27%, >22%, and ≥19%, respectively). Women at intermediate-to-high pregnancy
risk were also at the highest risk of experiencing a primary outcome during follow-up (Figures 3 and 4). This
finding was consistent regardless of the pregnancy risk
classification tool that was used (Table S7, Figures 3A,
3C, and 4A). The adjusted cumulative incidence of
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5–10‖
5–10

586 (70.2)

7 (14.9)

289 (28.5)

249 (29.8)

1–5‖

‖

6–10
12 (46.2)

69 (71.9)
84 (71.2)

27 (28.1)

173 (72.4)
82 (26.3)

‖

47 (42.0)

66 (27.6)

83 (22.7)
283 (77.3)
34 (8.5)

70 (62.5)

65 (58.0)

Intermediate-to-High Risk
n (%)

725 (71.5)
591 (58.3%)
1014§
Total

CARPREG indicates Canadian Cardiac Disease in Pregnancy study; and WHO, World Health Organization.
*CARPREG Risk Score: low risk=5%, intermediate-to-high risk = ≥25%.
†
CARPREG II Risk Score: low risk=5% to 15%, intermediate to high risk = ≥22%.
‡
Modified WHO: low risk=2.5% to 19% (WHO class I, II, III–III), intermediate-to-high risk = ≥19% (WHO class III or IV).
§
Total patients n=835 for WHO groups as cardiac lesions in 179 patients could not be classified into a WHO risk group.
‖
Exact numbers not provided because of Institute for Clinical Evaluative Sciences’ privacy policy.

10–15
35– 40
47
Other

423 (41.7%)

40 (85.1)

14 (53.8)

‖

1–5

‖

21–25
26
Ischemic

‖
‖

230 (73.7)

34 (28.8)
118 (100)
0
118
Isolated arrhythmia

161 (51.6)
312
Left sided valve

151 (48.4)

365 (91.5)

42 (37.5)
76 (67.9)
112

36 (32.1)

334 (83.7)
399
Congenital

Cardiomyopathy

65 (16.3)

Intermediate-to-High Risk
n (%)
Low Risk
n (%)
Low Risk
n (%)

Intermediate-to-High Risk
n (%)

a primary outcome at 20 years was 50.6%, 51.0%,
and 53.6% when intermediate-to-high pregnancy risk
groups were defined using CARPREG, CARPREG
II, and WHO classification tools, respectively. While
the risk of a primary outcome was elevated during
the early years of follow-
up in both pregnancy risk
groups, women in the intermediate-to-high pregnancy
risk group had the highest risk (Figures 3B, 3D, and
4B). When the data were reanalyzed using separate
WHO classes, the results were similar to when the
WHO classes were combined into high and low-to-
intermediate categories. The adjusted cumulative incidence of a primary outcome in women in WHO classes
III and IV was 52.8% to 54.2% at 20 years, compared
with 12.5% for women in WHO class I. In contrast, the
comparison group’s corresponding cumulative incidence was 2.1% (Figure S6).

DISCUSSION

Total No.
Maternal Cardiac Lesion

CARPREG II Risk Score†
CARPREG Risk Score*

Maternal Cardiovascular Risk

Principal Cardiac Lesion in Heart Disease Group and Maternal Cardiovascular Risk at Time of Index Pregnancy
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Table 4.

Low Risk
n (%)
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WHO Classification‡,§
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In this large study of women with heart disease, adverse cardiovascular events occurred in ≈1 in 3 women
during the 20 years following pregnancy, representing a
20-fold increase in risk when compared with a matched
group of women without heart disease. Furthermore,
many women with heart disease required therapeutic
cardiac procedures during this same period. Women
with heart disease were also more likely to develop
new hypertension or diabetes mellitus when compared
with women without heart disease. Risk stratification
tools used to predict cardiovascular complications
in pregnant women with heart disease, such as the
CARPREG risk score or the WHO classification, were
also helpful in identifying those women at highest risk
of long-term cardiovascular complications.
The hemodynamic and metabolic changes associated with pregnancy are responsible for the higher
frequency of maternal and feto-neonatal complications
reported in pregnant women with preexisting heart
disease compared with pregnant women without
heart disease.3,5–8 Whether these pregnancy changes
affect long-term outcomes in women with preexisting
heart disease has not been systematically examined.
Prior studies examining outcomes after pregnancy in
women with heart disease have been limited, reporting
on only small numbers of women, following for relatively short time intervals after pregnancy, or lacking
comparison groups.39–42 Combining patient level and
administrative data allowed us to match and adjust
for confounding factors and capture outcome events
over a prolonged period of follow-up.13,15,35–37 The high
rate of occurrence of adverse cardiovascular events in
women with heart disease, when they were still relatively young (age 40–50 years), highlights the significant long-term burden of cardiovascular disease in this
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Figure 3. Pregnancy risk groups: adjusted time-to-event curves for primary outcome and hazard ratios.
Adjusted cumulative incidence of primary outcome and 95% CIs as a function of maternal cardiovascular risk during index pregnancy.
Incidence rates are separated into low pregnancy risk heart disease group vs intermediate-to-high pregnancy risk heart disease
group, as defined by the CARPREG (Canadian Cardiac Disease in Pregnancy) risk score (A),3 and the modified World Health
Organization classification system (C).14 Numbers at risk were obtained from unadjusted cumulative incidence curves. Comparison
group denotes matched community comparison group. Instantaneous hazard ratios (point estimates and 95% CIs) for the low (in blue)
and intermediate-to-high (in red) pregnancy risk groups corresponding to the CARPREG risk score (B) and WHO (D) risk classification
are shown (comparison group=referent).

population. The high rates of long-term cardiovascular
events in these young women with heart disease may
represent the natural history of their underlying cardiac disease. It is also possible that the hemodynamic
stress of pregnancy adversely affects cardiac structure
and function in women with preexisting heart disease
differently than women without heart disease.43 We
have reported that women with heart disease have
an exaggerated increase in B-type natriuretic peptide
during pregnancy, likely as a result of ventricular distention.44 Incomplete return of cardiac structure and
function back to the prepregnancy state may be a
partial reason for our observation that the risk of cardiac outcome was the highest in the earlier years of
follow-up.
To our knowledge, this study was the first to examine long-term major cardiovascular adverse events and
cardiovascular risk factors in women with preexisting
heart disease. Previous population studies in women
without heart disease have demonstrated the relationship between obstetric complications, such as gestational hypertension, maternal placental syndrome,
cesarean delivery, and congenital heart disease in
the offspring,13,15,35–37 and subsequent long-
term

cardiovascular outcomes in the mother. In our current
study, even after adjusting for the above-mentioned
risk factors, women with heart disease were still more
likely to develop new hypertension or diabetes mellitus
than women without heart disease. Their higher long-
term atherosclerotic risk is suggested by the higher rate
of myocardial infarction or stroke in the heart disease
group. Pregnancy-
related hypercoagulability, inflammatory activity, insulin resistance, and dyslipidemia are
more pronounced in women with gestational hypertension, with endothelial dysfunction thought to be the
link between gestational hypertension, placental disorders, and late atherosclerotic events.13,15,35–37 Since
pregnant women with heart disease are already at elevated risk for noncardiac pregnancy complications,8
it is possible that maternal heart disease may further
elevate their propensity for hypertension or insulin resistance. While the mechanisms underlying our study
findings will require further investigation, the combination of preexisting heart disease and increased risk for
atherosclerotic risk factors is an unfavorable combination and points to the need for continuing postpartum
surveillance and risk factor modification in this group
of women.
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We and others have derived and validated classification methods to predict the risk of maternal cardiovascular complications in pregnant women with heart
disease.9 Our study was the first to demonstrate that
previously derived pregnancy risk assessment tools to
predict maternal cardiovascular complications in pregnant women with heart disease,3,4,14 can be expanded
and used for risk stratification of long-term cardiovascular outcomes. When applying our study results, it
is important to note that CARPREG risk scores incorporate history of heart failure, arrhythmia, and stroke
before the index pregnancy and is independent of the
primary outcomes, which are measured after the index
pregnancy. Furthermore, in calculating the risk of primary outcomes in relationship to CARPREG and WHO
risk categories, we also adjusted for cardiovascular
events during pregnancy. As the long-term cardiovascular risk in low-risk groups such as WHO class I was
higher than matched comparison groups, our study
findings are a reminder that “low risk” does not mean
“no risk.” Our study findings simplify risk assessment
for the clinician who can identify pregnancy-
related
and long-term cardiovascular risk with 1 risk assessment tool. Importantly, this ability to risk stratify long-
term risk was consistently observed with the 3 different
pregnancy risk classification tools that were evaluated.
In addition, the above-
mentioned risk assessment
tools include the wide spectrum of maternal heart disease seen in women of childbearing age.
The strength of this study was the combined use
of patient-level and administrative data. The use of

Long-Term Outcomes After Pregnancy

patient-
level data enabled the characterization of
the pregnancy risk profile of the women with heart
disease. The use of administrative healthcare databases enabled us to identify a comparable group of
women without heart disease from the Ontario population, as well as determining outcomes without loss
of follow-
up. By using birth records from Ontario,
Canada’s most populous province, we were able to
identify a comparison group that was similar to the
heart disease group on key parameters other than
maternal heart disease. As we used validated administrative databases that captured both ambulatory
encounters and hospitalization, we are able to provide a more accurate determination of the frequency
of late cardiovascular outcomes. This research approach also allowed for adjustment for the effects of
subsequent pregnancies on outcomes. Our study
was not designed to address whether pregnancy accelerates clinical or lesion progression in women with
heart disease,40– 42 as it would be difficult to identify a
comparable group of women with heart disease who
never underwent pregnancy. A population-
based
study from Canada reported that 80% of women of
childbearing age with congenital heart disease have
at least 1 pregnancy, with absolute number and
rates of pregnancy increasing with time.2 In addition
to the progressive decline in the number of women
with heart disease who do not undergo pregnancy,
women with heart disease who did not undergo
pregnancy may differ from women with heart disease who underwent pregnancy in demographics,

Figure 4. CARPREG (Canadian Cardiac Disease in Pregnancy) II adjusted time-to-event curves for primary outcome and
hazard ratios.
A, Adjusted cumulative incidence of primary outcome (with 95% CIs) as a function of maternal cardiovascular risk during index
pregnancy in the low pregnancy and intermediate-to-high (Int-High) pregnancy risk heart disease groups, as defined by the CARPREG
II risk score.4 Comparison group denotes matched community comparison group. No at risk denotes number at risk from unadjusted
cumulative incidence curves. B, Instantaneous hazard ratios (with 95% CIs) of primary outcome (matched community group=referent)
as a function of time, in the low (in blue) and intermediate-to-high (in red) risk groups corresponding to the CARPREG II risk score.
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comorbidities, or prognosis. Our study results are
applicable only to women with pregnancies that
progress beyond 20 weeks and women who survived beyond the postpartum period. However, we
have previously reported that 96% of pregnancies
in women with heart disease progressed beyond
20 weeks.4 There were <6 maternal deaths during
the index pregnancy in this study. The proportion of
mortality from cardiovascular causes may be underreported, as cause of death is based on certificates
of death. While we were not able to determine the
role of postpregnancy care in determining outcomes,
our analyses adjusted for baseline demographics and
socioeconomic status. However, the generalizability
of our study findings was optimized by the determination of outcomes using standardized hospital admissions and ambulatory visit databases, including a
large study group with a spectrum of cardiac lesions
and pregnancy risks, and conducted in women who
have universal access to health care.

CONCLUSIONS AND IMPLICATIONS
FOR CLINICAL PRACTICE
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Following pregnancy, women with heart disease are at
high risk for adverse long-term cardiovascular outcomes
including new hypertension or diabetes mellitus. Our
findings highlight the importance of ongoing surveillance
and risk factor modification in these young women after
pregnancy. Current tools for cardiovascular risk assessment during pregnancy can also be used to risk stratify
for long-term cardiovascular risk after pregnancy.
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Table S1. STROBE Statement.
Recommendation

Item

Where
Reported

Title and abstract

1

(a) Indicate the study’s design with a commonly used term in the title or the abstract

Abstract

(b) Provide in the abstract an informative and balanced summary of what was done and what

Abstract

was found
Introduction
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Background/rationale

2

Explain the scientific background and rationale for the investigation being reported

Introduction

Objectives

3

State specific objectives, including any prespecified hypotheses

Introduction

Study design

4

Present key elements of study design early in the paper

Methods

Setting

5

Describe the setting, locations, and relevant dates, including periods of recruitment, exposure,

Methods

Methods

follow-up, and data collection
Participants

6

(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of

Methods

participants. Describe methods of follow-up
(b) Cohort study—For matched studies, give matching criteria and number of exposed and
unexposed

Methods

Variables

Data sources/

7

8

measurement

Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers.

Methods

Give diagnostic criteria, if applicable

Tables S2-S5

For each variable of interest, give sources of data and details of methods of assessment

Methods

(measurement). Describe comparability of assessment methods if there is more than one group

Table S2

Bias

9

Describe any efforts to address potential sources of bias

Methods

Study size

10

Explain how the study size was arrived at

Methods

Quantitative variables

11

Explain how quantitative variables were handled in the analyses. If applicable, describe which

Methods

groupings were chosen and why

Tables S2-S5

(a) Describe all statistical methods, including those used to control for confounding

Methods

(b) Describe any methods used to examine subgroups and interactions

Methods

(c) Explain how missing data were addressed

Methods

(d) Cohort study—If applicable, explain how loss to follow-up was addressed

N/A

(e) Describe any sensitivity analyses

N/A

Statistical methods
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N/A, not applicable

12

Table S2. Description of ICES Databases and Algorithms and their role in the current study.
Original Validation
How the data were

Measures for ICES

Name of Data Base

Description

Type of data utilized

utilized in the study

Derived Databases

Canadian Institute for

Hospital discharge data since

•

Dates of

•

Cohort identification

Not applicable

Health Information

1988

hospitalization

•

Baseline

Discharge Abstract

•

Procedures

Database (DAD)

•

Diagnoses

•

Comorbidities
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•

Outcome

•

Cohort identification

•

Outcome

Ontario Mother-Baby

Linked DAD of inpatient

Linked Dataset

admission of mother and

(MOMBABY)

baby since 1988

Registered Persons

Demographic data of anyone

•

Date of birth/death

•

Cohort identification

Database (RPDB)

who has received Ontario

•

Sex

•

Baseline

health care number since

•

Geographic

1990

Diagnostic codes

characteristics

information

characteristics
•

Outcome

Not applicable

Not applicable

•

Time period of
insurance
coverage

Ontario Health

All reimbursement claims by

•

Diagnostic codes

•

Cohort identification

Insurance Plan (OHIP)

registered health care

•

Procedure codes

•

Baseline

claims database

providers since 1991

characteristics
•

Ontario Registrar

Cause of death (as recorded

General (ORGD)

on medical certificate of

Not applicable

Outcome
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Diagnostic codes

Outcome

Not applicable

Baseline characteristics

Not applicable

Baseline characteristics

Not applicable

death) since 1979
Ontario Health care

Ontario health care

Index birth at acute

institutions (INST)

institutions

care obstetric referral
center

Ontario Cancer Registry

Registry of all Ontario

Record of patient as

(OCR)

residents diagnosed with or

being in the registry

died from cancer except nonmelanoma skin cancer since
1964

Canadian Institute for

Individual level data for

Health Information

institutional-based

National Ambulatory

ambulatory care including

Care Reporting System

care provided in emergency

(NACRS)

departments and out-patient

Diagnostic codes

•

Cohort identification

•

Baseline

Not applicable

characteristics

clinics since 2000, and day
surgeries since 1988
Same Day Surgery

Database of same day

Procedural or

(SDS)

surgeries since 1991

diagnostic code

•
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Validated dataset to identify

(ETHNIC)26

Chinese or South Asian

Ethic Groups

Outcome

Baseline characteristics

•

Sensitivity 50% 80%

•

Specificity 100%

Baseline

•

Sensitivity 90%

characteristics

•

Specificity 99%

ethnicity based on surname

Ontario Diabetes

Validated dataset of Ontario

Record of patient as

Database (ODD)21, 28

residents identified as having

being in the dataset

diabetes mellitus since 1991

Not applicable

characteristics
•

Ethnicity dataset

Baseline

•

•

Outcome

Ontario Myocardial

Validated dataset of Ontario

Record of patient as

Infarction Database

residents identified as having

being in the dataset

(OMID)27

myocardial infarction since

•

Baseline

•

Sensitivity 89%

characteristics

•

Specificity 93%

•

Outcome

•

Baseline

•

Sensitivity 72%

characteristics

•

Specificity 95%

1992
Ontario Hypertension

Validated dataset of Ontario

Record of patient as

database (HYPER)25

residents identified as having

being in the dataset

hypertension since 1988

•

Outcome

•

Baseline

•

Sensitivity 81%
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Ontario Asthma

Validated dataset of Ontario

Record of patient as

database (ASTHMA)18

residents diagnosed with

being in the dataset

characteristics

•

Specificity 90%

Baseline characteristics

•

Sensitivity 85%

•

Specificity 95%

asthma since 1991
Ontario Chronic

Validated dataset of Ontario

Record of patient as

obstructive pulmonary

residents 35 years or older

being in the dataset

disease database

diagnosed with COPD since

(COPD)19

1991

Ontario Congestive

Validated dataset of Ontario

Record of patient as

•

Covariate

•

Sensitivity 85%

Heart Failure database

residents 40 years or older

being in the dataset

•

Outcome

•

Specificity 97%

(CHF)29

diagnosed with congestive
heart failure since 1988

Atrial fibrillation (AF)

Any of: hospitalization or an

•

Sensitivity 89%

Algorithm 30

emergency room code for AF

•

Specificity 99%

or 4 physician billing code
for AF in 1 yr
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Table S3. Prognostic Risk Score Utilized for Matching.

•

Group in which baseline model was derived: Women from Ontario that had a recorded birth during 1994 to 2015 period

•

Dependent variable: Time to the first of any event during follow up including death, heart failure, myocardial infarction, stroke, arrhythmia, or
atrial fibrillation.

•

Independent variable (in binary format) at index birth

i.

Any comorbid condition (referent =no) : Chronic Hypertension, Diabetes mellitus, Pulmonary disease, Renal disease, Cancer, Non
cancerous thyroid disease, Collagen vascular disease, Dyslipidemia, Obesity, Substance abuse, Cerebrovascular disease, or Peripheral
vascular disease
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ii.

Fertility therapy (referent =no)

iii.

Cesarean section (referent =no)

iv.

Ethnic (South Asian or Chinese vs other=referent)

v.

Multi fetal births (referent = no)

vi.

Delivery at tertiary obstetric center (referent = no)

vii.

Gestational diabetes during index pregnancy (referent = no)

Table S4. Variables used to define the cohort entry and exclusion criteria, as well as the study exposure, outcome, and adjustment variables.
Diagnostic or Procedural Codes
Assessment

Timing

Parameter

Cohort

April 1, 1991 -

Births

entry

December 31, 2019

ICD-9 or CCP (ICD-10 or CCI)

Other sources
MOMBABY*
Cohort entry date = date

criterion

of index birth

Cohort

male, non-Ontario resident,

exclusion

or death within 6 months of

criteria

index birth

RPDB†
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Prior to cohort

Cardiac Diagnosis

391-398,402-429, 6738, 6740, 745-7474, 48, 49,

OHIP diagnostic codes‡

entry date

(for community

(1HZ80, 1IJ50, 1IJ54, 1IJ55, 1IJ57, 1IJ76, 1IJ80,

390, 391, 394, 398, 402,

comparison group

1IJ86, 1IK80, 1IK87, 1IL35, 2IL70, I01, I020,

410, 412, 413, 415, 426,

only)

I05- I52, Q20- Q26, O903)

427, 428, 429, 745, 746,
747

Prior to cohort

Surgery or catheter

4702-4703, 4712- 4713, 4722- 4729, 4781 -

OHIP Fee Codes‡

entry date (age at

intervention on cardiac

4784, 4791– 4794, 5034, (1HJ, 1HM80, 1HN,

R729, R730,

index birth)

valves, thoracic aorta, or

1HP71 - 1HP87, 1HR, 1HS, 1HT, 1HU, 1HV,

R736, R773,

congenital cardiac lesions,

1HX, 1IA8, 1IB8, 1IC50,1IC80)

R774, R930,

Diagnostic or Procedural Codes
Assessment

Timing

Parameter

ICD-9 or CCP (ICD-10 or CCI)

Other sources

prior to cohort entry date

Z461, R733,

(community comparison

R720, R724, R772, R728

group only)
Prior to cohort

Coronary revascularization

entry date

(surgical or catheter; for

480-483, (1IJ50, 1IJ55, 1IJ57, 1IJ76, 1IJ80)

community comparison
group only)
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Prior to cohort

Cardiac arrhythmia

496, 497, 498, (1HZ53, 1HH59, 1HB53, 1HD55,

entry date

intervention (pacemaker,

1HB55, 1HZ38, 1HZ55)

ablation, defibrillator) for
community comparison
group only)
Prior to cohort

Cardiac transplantation or

entry date

cardiac assist device (for
community comparison
group only)

456, 495, (1HY85, 1HZ85, 1HP53)

Diagnostic or Procedural Codes
Assessment

Timing

Parameter

ICD-9 or CCP (ICD-10 or CCI)

Other sources

Study

April 1, 1991 –

Death during follow up (>6

RPDB†

outcomes

December 31, 2019

mos after index birth)

ORGD§

April 1, 1991 –

Cardiovascular death during

RPDB†

December 31, 2019

follow up (>6 mos after

ORGD§

index birth)
April 1, 1991 –

New congestive heart failure

December 31, 2019

during follow up (>6 mos

428, 5184, (I50, J81)

Ontario Congestive
Heart Failure database
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after index birth)
April 1, 1991 –

New myocardial infarction

December 31, 2019

during follow up (>6 mos

410, (I21)

Infarction Database

after index birth)
April 1, 1991 –

New Arrhythmia (any of

4260, 4270 – 4275, (I442, I46, I470 - I472, I479,

December 31, 2019

supraventricular or atrial

I48, I490)

tachycardia, atrial fibrillation
or flutter, ventricular
tachycardia, ventricular

Ontario Myocardial

Diagnostic or Procedural Codes
Assessment

Timing

Parameter

ICD-9 or CCP (ICD-10 or CCI)

Other sources

fibrillation, paroxysmal
tachycardia, cardiac arrest,
complete heart block) during
follow up (>6 mos after
index birth)
April 1, 1991 –

New Atrial fibrillation

Atrial fibrillation

December 31, 2019

during follow up (>6 mos

algorithm
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after index birth)

•

OHIP‡

•

Canadian Institute for
Health Information

•

National Ambulatory
Care Reporting System

April 1, 1991 –

New stroke (central nervous

December 31, 2019

system hemorrhage,
thrombosis, or embolism)

430 – 436, 3623, (I60 - I64, H34)

Diagnostic or Procedural Codes
Assessment

Timing

Parameter

ICD-9 or CCP (ICD-10 or CCI)

Other sources

during follow up (>6 months
after index birth)
April 1, 1991 –

New Diabetes mellitus

Ontario Diabetes

December 31, 2019

during follow up (>42 days

Database

after birth)
April 1, 1991 –

New Hypertension during

Ontario Hypertension

December 31, 2019

follow-up (>90 days after

database
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birth)

Covariates

April 1, 1991 –

Cardiovascular procedure

Same codes as above (listed under exclusion criteria for comparison group)

December 31, 2019

during follow-up (6 months),

for: 1) Surgery or catheter intervention on cardiac valves, thoracic aorta, or

excluding 9 months

congenital cardiac lesions; 2) Coronary revascularization; 3) Cardiac

preceding subsequent births

arrhythmia intervention; 4) Cardiac transplantation or cardiac assist device

At date of cohort

Age, Income quintile,

RPDB†; Canadian

entry

Rurality, Residence within

Institute for Health

Toronto Metropolitan Area,

Information Discharge

fiscal year of cohort entry

Abstract Database

Diagnostic or Procedural Codes
Assessment

Timing

Parameter

ICD-9 or CCP (ICD-10 or CCI)

Other sources

At date of cohort

Ethnic group

Ethnicity dataset

Hypertension

Ontario Hypertension

entry
Prior to date of
cohort entry

database (exclude
diagnosis within 150
days prior to birth)

Prior to date of

Diabetes mellitus
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cohort entry

Ontario Diabetes
Database (exclude
diagnosis within 120
days prior to birth and 90
days after birth)

Prior to date of

Cancer

Ontario Cancer Registry

Pulmonary disease

Ontario Asthma &

cohort entry
Prior to date of
cohort entry

Chronic obstructive

Diagnostic or Procedural Codes
Assessment

Timing

Parameter

ICD-9 or CCP (ICD-10 or CCI)

Other sources
pulmonary disease
databases

Within 3 years

Renal Disease

5845- 5849, 6693, 9585, 6343, 6353, 6363, 6373,

OHIP Diagnostic Codes‡

prior to cohort

6383, 6393, 2504, 2741, 403, 404, 405, 4401,

403, 581, 585

entry date

581- 583, 585- 588, 5900, 5937, 791, 7944,
(N17, O084, T795, O904, E1020, E1120, E1121,
M1039, I12, I13, I150, M310, N01, N03- N08,
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N11- N12, N137- N139, N14- N16)
Within 3 years

Non Cancer Thyroid Disease

226, 242, 244, 245, (D34, E032- E035, E038-

OHIP Diagnostic Codes‡

E039, E05- E06)

226, 242, 244, 245

7100- 7104, 7108- 7109, 7140- 7144, 7149,

OHIP Diagnostic

prior to cohort

(M313, M318, M319- M320, M32- M35, M368,

Codes‡

entry date

M05- M07)

710, 714, 720- 721, 739

prior to cohort
entry date
Within 3 years

Collagen Vascular Diseases

Diagnostic or Procedural Codes
Assessment

Timing

Parameter

ICD-9 or CCP (ICD-10 or CCI)

Other sources

Within 3 years

Cerebrovascular disease

433- 434, 436- 437, 5011-5012, (G46, I63- I66,

OHIP Diagnostic Codes‡

I672, I678, 1JE57, 1JW57, 1JX57, 1JW76)

432, 436, 437

4400, 4402, 444, 5018, 5028, 5038, 5124- 5126,

OHIP Diagnostic Code‡

prior to cohort

5129, (1JM76, 1JX76, 1KA76, 1KE76, 1KG57,

443

entry date

1KT76, 1ID76, 1KG76, 1KG87, I700, I702, I74)

prior to cohort
entry date
Within 3 years

Within 3 years

Peripheral vascular disease

Fertility treatment

V261, V268, 8192, (Z311 - Z313, 1RM83)
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prior to cohort

OHIP Procedural code‡
G334

entry date
Within 3 years

Dyslipidemia

2720 -2725, (E78)

prior to cohort

OHIP Diagnostic Code‡
272

entry date
Within 3 years
prior to cohort
entry date

Obesity

2780, (E66)

OHIP Diagnostic Code‡
278

Diagnostic or Procedural Codes
Assessment

Timing

Parameter

ICD-9 or CCP (ICD-10 or CCI)

Other sources

Within 3 years

Smoking or substance abuse

291-292, 2940, 303 – 305, 6483, 6555, 980, (F10

OHIP Diagnostic Codes‡

prior to cohort

- F19, F55, G312, O354 -O355, T51, T652, Z720

291-292, 303 - 305

entry date

- Z722)

Within 3 years

Any births (livebirths or

prior to cohort

stillbirths) prior to index

entry date

birth

At cohort entry

Multi-fetal pregnancy

MOMBABY*
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V311, V312, V321, V322, V341, V342, V351,

MOMBABY*:

date (date of index

V352, V361, V362, V371, V372, V272, V273,

B_Multibirth or

birth)

V274, V275, V276, V277, (Z372, Z373, Z374,

M_Multibirth

Z375, Z376, Z377, Z3790, O30, O31)
At cohort entry

Delivery at tertiary obstetric

Ontario Health care

date (date of index

centres

institutions

birth)
From start of

Fetus or newborn with

pregnancy until 1

congenital cardiac lesion

year post cohort

745 – 747, (Q20 - Q26)

Diagnostic or Procedural Codes
Assessment

Timing

Parameter

ICD-9 or CCP (ICD-10 or CCI)

Caesarean delivery

86, (5MD60)

Within 9 months of

Cardiac event related

Same as above codes for outcomes (congestive

cohort entry date

admission (Heart failure,

heart failure, arrhythmia, stroke, or myocardial

(date of index

arrhythmia, stroke, or MI)

infarction)

birth), and up to 6

during index pregnancy

Other sources

entry date (date of
index birth)
At cohort entry
date (date of index
birth)
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months after.
Within 9 months of

Obstetric event related

6408 – 6413, 6418 – 6419, 6567, 6442, 6581,

MOMBABY*

cohort entry date

admission (antepartum

6440, 765, 666, 6420, 6424 – 6427, 6429, 6423,

Stillbirth or birth <37

including hospital

bleed, preterm birth or

6565, 7649, 7680 - 7681, 6564, V271, V273 -

weeks gestation age

stay related to

rupture membrane, post

V274, V276 - V277, (O2080, O2090, O365,

OHIP diagnostic code‡

index birth

partum hemorrhage,

O4381, O4410, O45, O46, O431, O43801 -

642

gestational hypertension/

O43819, O439, O60, O4201, O4211, P059, P072

Diagnostic or Procedural Codes
Assessment

Timing

Parameter

ICD-9 or CCP (ICD-10 or CCI)

preeclampsia, stillbirth, fetal

- P073, O72, O11, O13 - O16, P95, Z371, Z373 -

death, abruptio placenta,

Z374, Z376 -Z377, O364)

Other sources

placental infarction, poor
fetal growth)
Within 9 months of

Gestational Diabetes

64800 – 64804, (O244, O248, O249)

cohort entry
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After cohort entry

Subsequent births after index

date

birth

MOMBABY*

ICD-9, International Classification of Diseases, 9th revision; CCP, /Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures;
ICD-10, International Classification of Diseases, 10th revision; CCI, Canadian Classification of Health Interventions, * MOMBABY database;
†Registered Persons Database; ‡ Ontario Health Insurance Plan; § Ontario Registrar General

Table S5. Summary of the 3 Methods to Predict Maternal Cardiovascular Risks in Pregnant Women with Heart Disease.
Name

Predictors and Risk Score Point Value

Calculation of Risk Score

Risk Groups and Predicted
Risk of Maternal
Cardiovascular Events
during Pregnancy and
subsequent 6 months post
delivery

•
CARPREG
Downloaded from http://ahajournals.org by on June 21, 2022

CARPREG II

New York Heart Association class III or IV or cyanosis (1

Each predictor = 1 point

Score 1, event rate 27%

point)
•

Systemic ventricular EF <40% (1 point)

•

Left heart obstruction (1 point)

•

Cardiac event prior to current pregnancy (1 point)

•
•

Score 0, event rate 5%

Risk score = sum of points

Score >1, event rate 75%

Cardiac event prior to current pregnancy (3 points)

Weighted risk score

Score 0 to 1, event rate 5%

Baseline New York Heart Association III/IV or Cyanosis (3

Risk score = sum of points

Score 2, event rate 10%

points)

Score 3, event rate 15%

•

Systemic ventricular EF <55% (2 points)

Score 4, event rate 22%

•

Left heart obstruction (mitral valve area<2 cm2 or aortic valve

Score > 4, event rate 41%

area<1.5 cm2, or peak left ventricular outflow tract

gradient>30 mmHg) or a least moderate-severe mitral
regurgitation (2 points)

WHO*

•

Mechanical valve (3 points)

•

Pulmonary hypertension (2 points)

•

Coronary artery disease (2 points)

•

High-risk aortopathy (2 points)

•

No prior cardiac interventions (1 point)

•

Late pregnancy assessment (1 point)
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WHO class I *

Class I, event rate 2.5% - 5%

•

Small or mild pulmonary stenosis, patent ductus arteriosus,

Class II, event rate 5.7% -

mitral valve prolapse

10.5%

Successfully repaired simple lesions (atrial or ventricular

Class II–III, event rate 10% -

septal defect, patent ductus arteriosus, anomalous pulmonary

19%

venous connection)

Class III, event rate 19% -

Atrial or ventricular ectopic beats, isolated

27%

•

•

WHO class II *

Class IV, event rate 40% -

•

Unoperated atrial or ventricular septal defect

100%

•

Repaired tetralogy of Fallot

•

Most arrhythmias (supraventricular arrhythmias)

•

Turner syndrome without aortic dilation

WHO class II–III *
•

Mild left ventricular impairment (EF>45%)

•

Hypertrophic cardiomyopathy

•

Native or tissue valvular heart disease not considered WHO I
or IV (mild mitral stenosis, moderate aortic stenosis)

•

Marfan or other HTAD † syndrome without aortic dilatation

•

Aorta <45 mm in association with bicuspid aortic valve
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pathology
•

Repaired coarctation

Atrioventricular septal defect
WHO class III *
•

Moderate left ventricular impairment (EF 30-45%)

•

Previous peripartum cardiomyopathy without residual left
ventricular impairment

•

Mechanical valve

•

Systemic right ventricle with good or mildly decreased
ventricular function

•

Fontan circulation if otherwise well and the cardiac condition
uncomplicated

•

Unrepaired cyanotic heart disease

•

Other complex congenital heart disease

•

Moderate mitral stenosis

•

Severe asymptomatic aortic stenosis

•

Moderate aortic dilation (40–45 mm in Marfan syndrome or

Downloaded from http://ahajournals.org by on June 21, 2022

other HTAD, † 45–50 mm in bicuspid aortic valve, Turner
syndrome with aortic size index 20-25mm/m2, tetralogy of
Fallot <50mm)
•

Ventricular tachycardia

WHO class IV*
•

Pulmonary arterial hypertension

•

Severe systemic ventricular dysfunction (Ejection
fraction<30% or New York Heart Association Functional class
III-IV)

•

Previous peripartum cardiomyopathy with any residual left
ventricular impairment

•

Severe mitral stenosis

•

Severe symptomatic aortic stenosis

•

Systemic right ventricle with moderate or severely decreased
ventricular function

•

Severe aortic dilatation (>45 mm in Marfan syndrome or other
HTAD, † >50 mm in bicuspid aortic valve, Turner syndrome
with aortic size index >25mm/m2, tetralogy of Fallot >50mm)
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•

Vascular Ehlers-Danlos

•

Severe (re)coarctation

•

Fontan with any complication

* modified World Health Organization; † heritable thoracic aortic disease

Table S6. Principal Cardiac Lesion in Heart Disease Group, Time to Event, and Nature of Long-Term Events.

Maternal
Cardiac Lesion

Total

Frequency of

Unadjusted Rate (95%

Time to Primary

Frequency of Components of Primary

No.

Primary

CI) of Primary

Composite Outcome

Composite Outcome *

Composite

Composite Outcome per

Yrs

Outcome

1000 person-years

Median (IQR)

Death

HF

AF

Arr

Stroke

MI
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Congenital

399

85

16.9 (13.7-20.8)

6.6 (2.7-13.5)

10

34

54

42

1-5 †

1-5 †

Cardiomyopathy

112

53

54.7 (42.1-71.1)

4.1 (1.8-8.8)

10

26

38

27

1-5 †

1-5 †

Left sided valve

312

88

21.4 (17.4-26.4)

6.5 (3.5-12.0)

14

43

66

43

12

1-5 †

Isolated

118

53

58.3 (45.0-75.7)

1.8 (0.9-4.9)

1-5 †

1-5 †

41

23

0

0

Ischemic

26

8

29.4 (14.9-58.3)

3.6 (2.4-4.9)

1-5 †

1-5 †

1-5 †

1-5 †

0

0

Other

47

11

24.2 (13.5-43.3)

3.0 (1.5-6.3)

1-5 †

7

1-5 †

1-5 †

0

0

arrhythmia

*not mutually exclusive; † low counts suppressed as per ICES privacy policy; HF, heart failure; AF, atrial fibrillation, Arr, arrhythmia; MI,
myocardial infarction

Table S7. Adjusted Model for Primary Outcome Using Pregnancy Risk Classification Systems.
CARPREG *
Parameter

Hazard Ratio (95%

WHO †

CARPREG II *
P value

CI)

Hazard Ratio (95%

P value

CI)

P value

(95% CI)

Heart Disease Group: Low

11.4 (7.7 - 17.3) ‡

Pregnancy Risk (Community

See Figure 3B for

See Figure S4B for

See Figure 3D for

comparison group = referent)

instantaneous hazard

instantaneous hazard

instantaneous

ratios over time

ratios over time

hazard ratios over

<0.001

15.0 (10.4 - 22.4) ‡

Hazard Ratio

<0.001

16.4 (10.9 - 25.6) ‡

<0.001

time
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Heart Disease Group:

34.2 (23.7 - 51.0) ‡

Intermediate to High Pregnancy

See Figure 3B for

See Figure S4B for

See Figure 3D for

Risk (Community comparison

instantaneous hazard

instantaneous hazard

instantaneous

group = referent)

ratios over time

ratios over time

hazard ratios over

<0.001

34.7 (23.6 - 52.3) ‡

<0.001

37.7 (24.9 - 59.4) ‡

<0.001

time
Obstetric complication during
index pregnancy

1.3 (1.0-1.6)

0.069

1.2 (1.0-1.5)

0.12

1.1 (0.9-1.5)

0.32

Cardiac complication during

2.4 (1.7-3.4)

<0.001

2.5 (1.7-3.5)

<0.0001

2.8 (2.0-4.0)

<0.001

1.6 (1.1-2.2)

0.017

1.4 (0.9-1.9)

0.12

1.4 (1.0-2.0)

0.058

1.1 (0.9-1.3)

0.51

1.1 (0.9-1.3)

0.54

1.1 (0.9-1.4)

0.43

Status of subsequent pregnancy

2.0 (1.3-3.0)

0.0031

2.0 (1.3-3.0)

0.0021

1.9 (1.2-2.9)

0.011

Charlson index score > 1

1.7 (1.1-2.5)

0.017

1.5 (1.0-2.3)

0.047

1.4 (0.8-2.2)

0.20

Age at index birth

1.04 (1.02-1.06)

0.0021

1.04 (1.01-1.06)

0.0033

1.04 (1.01-1.06)

0.0086

Low residential income area

1.0 (0.8-1.3)

0.92

1.04 (0.8-1.3)

0.75

1.0 (0.8-1.3)

0.72

Greater Toronto Metropolitan

1.1 (0.9-1.4)

0.52

1.0 (0.8-1.3)

0.75

1.1 (0.8-1.4)

0.53

Index birth is first pregnancy

0.9 (0.7-1.1)

0.39

0.9 (0.7-1.1)

0.36

0.8 (0.6-1.1)

0.20

Fiscal year of index birth

0.98 (0.96-0.99)

0.041

0.98 (0.96-1.00)

0.067

0.99 (0.96-1.01)

0.25

index pregnancy
Baby born with congenital
cardiac lesion
Number of subsequent
pregnancies
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Area residence

* Canadian Cardiac Disease in Pregnancy Study; † modified World Health Organization classification; WHO; ‡ hazard ratio from analyses
assuming constant proportional hazard between heart disease and comparison groups

Figure S1. Flow Chart Showing Cohort Formation.
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Flow Chart showing formation of heart disease and community comparison groups.

Figure S2. Unadjusted Time-to-Event Curves for Primary Outcome.

Downloaded from http://ahajournals.org by on June 21, 2022

Unadjusted cumulative incidence (with 95% confidence intervals) of primary outcome in heart disease
and matched community comparison group (comparison group).

Figure S3. Unadjusted Time-to-Event Curves for Selected Secondary Outcomes.
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Unadjusted cumulative incidence (with 95% confidence intervals) of heart failure (A), atrial fibrillation (B),
therapeutic cardiac procedures (C), and new hypertension or diabetes mellitus (D), in heart disease and
matched community comparison group (comparison group).

Figure S4. Unadjusted Time-to-Event Curves for Primary Outcome Stratified by Occurrence of
Pregnancy complications.

Downloaded from http://ahajournals.org by on June 21, 2022

Unadjusted comparison of outcome in heart disease and comparison groups as stratified by whether a
pregnancy complication (cardiac or obstetric) occurred during the index pregnancy. The unadjusted rate of
composite primary outcome (rate per 1000 person-years, 95%) was 37.2 (31.4-44.1), 20.5 (17.6-23.8), 1.5
(0.9-2.6), and 0.9 (0.6-1.5), corresponding to heart disease group with pregnancy complications (in brown),
heart disease group without pregnancy complications (in purple), comparison group with pregnancy
complications (in red), and comparison group without pregnancy complications (in green).

Figure S5. Adjusted Time-to-Event Curve for Death, Heart Failure, Stroke, or myocardial
infarction.
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Adjusted cumulative incidence of the primary outcome (all-cause mortality, heart failure, myocardial
infarction, or stroke) with 95% confidence intervals in the heart disease group and matched comparison
group. Numbers at risk were obtained from unadjusted cumulative incidence curves.

Figure S6. Adjusted Time-to-Event Curve for Primary Outcomes separated by individual WHO
Risk Groups.
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Adjusted cumulative incidence of primary outcome and 95% confidence intervals as a function of maternal
cardiovascular risk during index pregnancy. Incidence rates are separated into pregnancy risk groups
according to the modified World Health Organization classification system (WHO). Numbers at risk were
obtained from unadjusted cumulative incidence curves. Comparison group denotes matched community
comparison group.

